These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28255643)

  • 41. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of leprosy in a patient with rheumatoid arthritis during treatment with etanercept: a case report.
    Lluch P; Urruticoechea A; Lluch J; Moll MC; Matos M; Benet JM; Ene L; Cañete JD
    Semin Arthritis Rheum; 2012 Oct; 42(2):127-30. PubMed ID: 22542278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis.
    Berthold E; Månsson B; Gullstrand B; Geborek P; Saxne T; Bengtsson AA; Kahn R
    Scand J Rheumatol; 2018 Jan; 47(1):22-26. PubMed ID: 28485187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduction of autophagy and increase in apoptosis correlates with a favorable clinical outcome in patients with rheumatoid arthritis treated with anti-TNF drugs.
    Vomero M; Manganelli V; Barbati C; Colasanti T; Capozzi A; Finucci A; Spinelli FR; Ceccarelli F; Perricone C; Truglia S; Morrone S; Maggio R; Misasi R; Bombardieri M; Di Franco M; Conti F; Sorice M; Valesini G; Alessandri C
    Arthritis Res Ther; 2019 Jan; 21(1):39. PubMed ID: 30696478
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis.
    Blaschke S; Rinke K; Maring M; Flad T; Patschan S; Jahn O; Mueller CA; Mueller GA; Dihazi H
    Arthritis Res Ther; 2015 Mar; 17(1):45. PubMed ID: 25884688
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term survival of subcutaneous anti-tumor necrosis factor biological drugs administered between 2008 and 2012 in a cohort of rheumatoid arthritis patients.
    Alvarez Rivas N; Vazquez Rodriguez TR; Miranda Filloy JA; Garcia-Porrua C; Sanchez-Andrade Fernández A
    Reumatol Clin (Engl Ed); 2019; 15(1):54-57. PubMed ID: 28551175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis.
    Julià A; Fernandez-Nebro A; Blanco F; Ortiz A; Cañete JD; Maymó J; Alperi-López M; Fernández-Gutierrez B; Olivè A; Corominas H; Erra A; Acosta-Colman I; Alonso A; López-Lasanta M; Tortosa R; Tornero J; Marsal S
    Pharmacogenomics J; 2016 Apr; 16(2):147-50. PubMed ID: 25896534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis.
    Accortt NA; Schenfeld J; Chang E; Papoyan E; Broder MS
    Adv Ther; 2017 Sep; 34(9):2093-2103. PubMed ID: 28770517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
    Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy.
    Gonzalez-Gay MA; Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Llorca J
    Ann N Y Acad Sci; 2010 Apr; 1193():153-9. PubMed ID: 20398022
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy.
    Bibbo C; Goldberg JW
    Foot Ankle Int; 2004 May; 25(5):331-5. PubMed ID: 15134615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful etanercept use in an HIV-positive patient with rheumatoid arthritis.
    Kaur PP; Chan VC; Berney SN
    J Clin Rheumatol; 2007 Apr; 13(2):79-80. PubMed ID: 17414534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
    Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.
    Brunasso AM; Puntoni M; Gulia A; Massone C
    Rheumatology (Oxford); 2011 Sep; 50(9):1700-11. PubMed ID: 21690185
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.
    Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
    Rheumatology (Oxford); 2006 Oct; 45(10):1294-7. PubMed ID: 16603583
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
    Finckh A; Dehler S; Gabay C;
    Ann Rheum Dis; 2009 Jan; 68(1):33-9. PubMed ID: 18230627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.